Sort   by:  
 Page size 
UnknownMetabolic signature identifies novel targets for drug resistance in multiple myeloma.
Not available
S-EPMC4433568 | biostudies-literature
UnknownDual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Not available
S-EPMC2343604 | biostudies-literature
UnknownPhase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia.
Not available
S-EPMC8786275 | biostudies-literature
UnknownAntibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Not available
S-EPMC6030488 | biostudies-literature
UnknownEngineered nanomedicine for myeloma and bone microenvironment targeting.
Not available
S-EPMC4104924 | biostudies-literature
UnknownPyk2 promotes tumor progression in multiple myeloma.
Not available
S-EPMC4208283 | biostudies-literature
UnknownMicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
Not available
S-EPMC2710922 | biostudies-literature
UnknownCXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
Not available
S-EPMC4961259 | biostudies-literature
UnknownSpecific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Not available
S-EPMC9710471 | biostudies-literature
UnknownThe Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.
Not available
S-EPMC5439509 | biostudies-literature
Sort   by:  
 Page size